Literature DB >> 21052859

Radiofrequency ablation versus surgical resection for hepatocellular carcinoma in Childs A cirrhotics-a retrospective study of 1,061 cases.

Jiwei Huang1, Roberto Hernandez-Alejandro, Kristopher P Croome, Lvnan Yan, Hong Wu, Zheyu Chen, Pankaj Prasoon, Yong Zeng.   

Abstract

INTRODUCTION: The long-term outcomes of radiofrequency ablation (RFA) vs. surgical resection in cirrhotic patients with hepatocellular carcinoma (HCC) remain controversial. One thousand sixty-one cirrhotic HCC patients were included into a retrospective study. Four hundred thirteen received RFA and 648 received surgical resection.
RESULTS: Overall (OS), recurrence-free (RFS), and tumor-free survival (TFS) were compared between the two groups and in subgroup analyses. The 5-year OS and corresponding RFS as well as DFS were significantly higher in the surgical resection group compared with the RFA group (p < 0.001, p < 0.001, p < 0.001). In subgroup analyses of solitary HCC ≤3 cm, there was no significant difference in RFS between the two groups (p = 0.719). Nonetheless, surgical resection was superior to RFA for OS and TFS in this subgroup as well as for OS, RFS, and TFS in subgroup analyses for solitary lesions 3 cm < HCC < 5 cm and multifocal HCC. Serum AFP was the only significant predicting factor for all survival analyses.
CONCLUSIONS: When treating Childs A cirrhotic patients with solitary HCC larger than 3 cm but less than 5 cm, or with two or three lesions each less than 5 cm, surgical resection provides a better survival than RFA. When treating Childs A cirrhotics with solitary HCC ≤ 3 cm, RFA has a comparable RFS to surgical resection, but RFA is less invasive.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21052859     DOI: 10.1007/s11605-010-1372-y

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  30 in total

1.  Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function.

Authors:  Sung Noh Hong; Sun-Young Lee; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo; Jong Chul Rhee; Dongil Choi; Hyo Keun Lim; Kwang-Woong Lee; Jae Won Joh
Journal:  J Clin Gastroenterol       Date:  2005-03       Impact factor: 3.062

Review 2.  Radiofrequency ablation of malignant liver tumors.

Authors:  S A Curley
Journal:  Oncologist       Date:  2001

3.  [Radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis].

Authors:  Corinne Bonny; Armand Abergel; Pierre Gayard; Stéphane Chouzet; Sylvie Ughetto; Karem Slim; Ludovic Rosenfeld; Rémi Guillon; Laurent Poincloux; Gilles Bommelaer
Journal:  Gastroenterol Clin Biol       Date:  2002 Aug-Sep

Review 4.  Complications of radiofrequency coagulation of liver tumours.

Authors:  S Mulier; P Mulier; Y Ni; Y Miao; B Dupas; G Marchal; I De Wever; L Michel
Journal:  Br J Surg       Date:  2002-10       Impact factor: 6.939

5.  Intrahepatic metastases in hepatocellular carcinoma: evidence for spread via the portal vein as an efferent vessel.

Authors:  A Toyosaka; E Okamoto; M Mitsunobu; T Oriyama; N Nakao; K Miura
Journal:  Am J Gastroenterol       Date:  1996-08       Impact factor: 10.864

6.  Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma.

Authors:  Atsushi Sasaki; Seiichiro Kai; Yukio Iwashita; Seitaro Hirano; Masayuki Ohta; Seigo Kitano
Journal:  Cancer       Date:  2005-01-15       Impact factor: 6.860

7.  Hepatic resection for hepatocellular carcinoma. An audit of 343 patients.

Authors:  E C Lai; S T Fan; C M Lo; K M Chu; C L Liu; J Wong
Journal:  Ann Surg       Date:  1995-03       Impact factor: 12.969

Review 8.  Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future.

Authors:  W Y Lau; Thomas W T Leung; Simon C H Yu; Stephen K W Ho
Journal:  Ann Surg       Date:  2003-02       Impact factor: 12.969

9.  Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.

Authors:  Tsung-Ming Chen; Pi-Teh Huang; Ming-Hung Tsai; Lien-Fu Lin; Chung-Cheng Liu; Ka-Sic Ho; Chuan-Pau Siauw; Po-Liang Chao; Jai-Nien Tung
Journal:  J Gastroenterol Hepatol       Date:  2007-05       Impact factor: 4.029

10.  Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver.

Authors:  Marco Vivarelli; Alfredo Guglielmi; Andrea Ruzzenente; Alessandro Cucchetti; Roberto Bellusci; Claudio Cordiano; Antonino Cavallari
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

View more
  28 in total

1.  Risk factors for deterioration of long-term liver function after radiofrequency ablation therapy.

Authors:  Koichi Honda; Masataka Seike; Junya Oribe; Mizuki Endo; Mie Arakawa; Hiroki Syo; Masao Iwao; Masanori Tokoro; Junko Nishimura; Tetsu Mori; Tsutomu Yamashita; Satoshi Fukuchi; Toyokichi Muro; Kazunari Murakami
Journal:  World J Hepatol       Date:  2016-05-08

Review 2.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 3.  Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma.

Authors:  Francesco Tovoli; Giulia Negrini; Luigi Bolondi
Journal:  Hepat Oncol       Date:  2016-03-23

4.  Resection and radiofrequency ablation in the treatment of hepatocellular carcinoma: a single-center experience.

Authors:  Koray Karabulut; Federico Aucejo; Hizir Yakup Akyildiz; Allan Siperstein; Eren Berber
Journal:  Surg Endosc       Date:  2011-10-25       Impact factor: 4.584

5.  Reducing Pain by Artificial Ascites Infusion During Radiofrequency Ablation for Subcapsular Hepatocellular Carcinoma.

Authors:  Sae-Jin Park; Dong Ho Lee; Joon Koo Han
Journal:  Cardiovasc Intervent Radiol       Date:  2021-01-03       Impact factor: 2.740

6.  Modeling and validation of microwave ablations with internal vaporization.

Authors:  Jason Chiang; Sohan Birla; Mariajose Bedoya; David Jones; Jeyam Subbiah; Christopher L Brace
Journal:  IEEE Trans Biomed Eng       Date:  2014-10-15       Impact factor: 4.538

7.  Surgical resection versus open-approach radiofrequency ablation for small hepatocellular carcinomas within Milan criteria after successful transcatheter arterial chemoembolization.

Authors:  Jianyong Lei; Wentao Wang; Lunan Yan
Journal:  J Gastrointest Surg       Date:  2013-10       Impact factor: 3.452

8.  Could radiofrequency ablation replace liver resection for small hepatocellular carcinoma in patients with compensated cirrhosis? A 5-year follow-up.

Authors:  Jacopo Desiderio; Stefano Trastulli; Rosario Pasquale; Davide Cavaliere; Roberto Cirocchi; Carlo Boselli; Giuseppe Noya; Amilcare Parisi
Journal:  Langenbecks Arch Surg       Date:  2012-12-07       Impact factor: 3.445

9.  Earlier presentation and application of curative treatments in hepatocellular carcinoma.

Authors:  Susanna V Ulahannan; Austin G Duffy; Timothy S McNeel; Jonathan K Kish; Lois A Dickie; Osama E Rahma; Katherine A McGlynn; Tim F Greten; Sean F Altekruse
Journal:  Hepatology       Date:  2014-09-29       Impact factor: 17.425

10.  Surgical resection versus ablation for hepatocellular carcinoma ≤ 3 cm: a population-based analysis.

Authors:  John T Miura; Fabian M Johnston; Susan Tsai; Dan Eastwood; Anjishnu Banerjee; Kathleen K Christians; Kiran K Turaga; T Clark Gamblin
Journal:  HPB (Oxford)       Date:  2015-07-31       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.